Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians

European Journal of Preventive Cardiology

Volumn 22, Issue 4, 2015, Pages 468-477

  Rashid, Shirya ^a   Sniderman, Allan ^b   Melone, Michelle ^c   Brown, Patrick E ^d   Otvos, James D ^e,f   Mente, Andrew ^c,g   Schulze, Karleen ^c,g   Mcqueen, Matthew J ^a,c,g   Anand, Sonia S ^a,c,g   Yusuf, Salim ^a,c,g  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CANCER CARE ONTARIO   (Canada)

^e LIPOSCIENCE INC   (United States)

^f NORTH CAROLINA STATE UNIVERSITY   (United States)

^g HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

atherogenic dyslipoproteinemia; atherosclerotic cardiovascular diseases; Cholesteryl ester transfer protein (CETP); HDL; LDL; South Asians

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; CETP PROTEIN, HUMAN;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; ETHNIC GROUP; EUROPEAN; FEMALE; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOUTH ASIAN; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; BLOOD; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; DYSLIPIDEMIAS; EPIDEMIOLOGY; ETHNOLOGY; EUROPE; HEALTH DISPARITY; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; UPREGULATION;

ADULT; AGED; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; BIOMARKERS; CANADA; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; UP-REGULATION;

EID: 84924965009     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314528461     Document Type: Article

References (57)

1. Gupta M, Singh N, Verma S. South Asians and cardiovascular risk: What clinicians should know. Circulation. 2006 ; 113: e924 - e929
2. Gupta M, Brister S. Is South Asian ethnicity an independent cardiovascular risk factor?. Can J Cardiol. 2006 ; 22: 193-197
3. Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA. 2007 ; 297: 286-294
4. Patel JV, Caslake MJ, Vyas A, et al. Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. Atherosclerosis. 2010 ; 209: 579-584
5. Kolluri R, Pinedo D, Edmondson-Holt A, et al. Dyslipidemia in South Asians living in a western community. J Clin Lipidol. 2009 ; 3: 14-18
6. Enas EA, Mohan V, Deepa M, et al. The metabolic syndrome and dyslipidemia among Asian Indians: A population with high rates of diabetes and premature coronary artery disease. J Cardiometab Syndr. 2007 ; 2: 267-275
7. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004 ; 364: 937-952
8. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: The Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet. 2000 ; 356: 279-284
9. Costandi J, Melone M, Zhao A, et al. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ Res. 2011 ; 108: 727-742
10. Adiels M, Olofsson SO, Taskinen MR, et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008 ; 28: 1225-1236
11. Adiels M, Olofsson SO, Taskinen MR, et al. Diabetic dyslipidaemia. Curr Opin Lipidol. 2006 ; 17: 238-246
12. Després JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol. 2007 ; 6 (2). 51-59
13. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007 ; 116: 39-48
14. Lear SA, Humphries KH, Kohli S, et al. Visceral adipose tissue accumulation differs according to ethnic background: Results of the Multicultural Community Health Assessment Trial (M-CHAT). Am J Clin Nutr. 2007 ; 86: 353-359
15. Kohli S, Sniderman AD, Tchernof A, et al. Ethnic-specific differences in abdominal subcutaneous adipose tissue compartments. Obesity (Silver Spring). 2010 ; 18: 2177-2183
16. Sniderman AD, Bhopal R, Prabhakaran D, et al. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int J Epidemiol. 2007 ; 36: 220-225
17. Anand SS, Tarnopolsky MA, Rashid S, et al. Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). PLoS One. 2011 ; 6: e22112 - e22112
18. Canoy D, Cairns BJ, Balkwill A, et al. Coronary heart disease incidence in women by waist circumference within categories of body mass index. Eur J Prev Cardiol. 2013 ; 20: 759-762
19. Gehani AA, Al-Hinai AT, Zubaid M, et al. Association of risk factors with acute myocardial infarction in Middle Eastern countries: The INTERHEART Middle East study. Eur J Prev Cardiol 2012; 8: 1-8.
20. Dullaart RP, Constantinides A, Perton FG, et al. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: Possible contribution to an atherogenic lipoprotein profile. J Clin Endocrinol Metab. 2011 ; 96: 1077-1084
21. Stalenhoef AF, Davidson MH, Robinson JG, et al. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab. 2012 ; 14: 30-39
22. Ebenbichler CF, Laimer M, Kaser S, et al. Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1465-1469
23. Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: The prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation. 2004 ; 110: 1418-1423
24. Cuchel M, Rader DJ. Is the cholesteryl ester transfer protein proatherogenic or antiatherogenic in humans?. J Am Coll Cardiol. 2007 ; 50: 1956-1957
25. Mann CJ, Yen FT, Grant AM, et al. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 1991 ; 88: 2059-2066
26. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: Role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest. 2003 ; 33: 1051-1069
27. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther. 2006 ; 111: 893-908
28. Rashid S, Uffelman KD, Lewis GF. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications. 2002 ; 16: 24-28
29. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003 ; 23: 160-167
30. Rashid S, Barrett PH, Uffelman KD, et al. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol. 2002 ; 22: 483-487
31. Rashid S, Watanabe T, Sakaue T, et al. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: The combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003 ; 36: 421-429
32. Barter PJ, Kastelein JJ. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol. 2006 ; 47: 492-499
33. Keebler ME, Sanders CL, Surti A, et al. Association of blood lipids with common DNA sequence variants at 19 genetic loci in the multiethnic United States National Health and Nutrition Examination Survey III. Circ Cardiovasc Genet. 2009 ; 2: 238-243
34. Talmud PJ, Drenos F, Shah S, et al. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Genet. 2009 ; 85: 628-642
35. Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res. 2012 ; 53: 540-547
36. Dansky HM, Bloomfield D, Gibbons P, et al. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. Am Heart J. 2011 ; 162: 708-716
37. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 ; 363: 2406-2415
38. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial. JAMA. 2011 ; 306 (19). 2099-2109
39. Mackey RH, Greenland P, Goff DC Jr, et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2012 ; 60: 508-516
40. Parish S, Offer A, Clarke R, et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation. 2012 ; 125: 2469-2478
41. Chapman MJ, Le GW, Guerin M, et al. Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010 ; 31: 149-164
42. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J. 1998 ; 19: A24 - A30
43. Guerin M, Le Goff W, Lassel TS, et al. Proatherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: Impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 2001 ; 21: 282-288
44. Rashid S, Trinh DK, Uffelman KD, et al. Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglyceride-enriched versus native high-density lipoprotein apolipoprotein A-I. Circulation. 2003 ; 107: 3066-3072
45. Collet X, Tall AR, Serajuddin H, et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res. 1999 ; 40: 1185-1193
46. Xiao C, Watanabe T, Zhang Y, et al. Enhanced cellular uptake of remnant high-density lipoprotein particles: A mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ Res. 2008 ; 103: 159-166
47. Lamarche B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest. 1999 ; 103: 1191-1199
48. Nicholls SJ, Rye KA, Barter PJ. High-density lipoproteins as therapeutic targets. Curr Opin Lipidol. 2005 ; 16: 345-349
49. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: Focus on antioxidative activities. Curr Opin Lipidol. 2010 ; 21: 312-318
50. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002 ; 43: 1363-1379
51. Younis N, Sharma R, Soran H, et al. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol. 2008 ; 19: 378-384
52. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: Part II: Variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001 ; 104: 2855-2864
53. Lear SA, Toma M, Birmingham CL, et al. Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. Metabolism. 2003 ; 52: 1295-1301
54. Franssen R, Monajemi H, Stroes ES, et al. Obesity and dyslipidemia. Med Clin North Am. 2011 ; 95: 893-902
55. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology. 2007 ; 132: 2181-2190
56. Tan GD, Olivecrona G, Vidal H, et al. Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: Role of adipose tissue and skeletal muscle in response to rosiglitazone. Diabetologia. 2006 ; 49: 2412-2418
57. Rashid S, Uffelman KD, Barrett PH, et al. Effect of atorvastatin on high-density lipoprotein apolipoprotein A - I production and clearance in the New Zealand white rabbit. Circulation. 2002 ; 106: 2955-2960